🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Biomarin Pharmaceutical Inc (B1MR34)

B3
Currency in BRL
194.00
0.00(0.00%)
Closed
B1MR34 Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
194.00194.00
52 wk Range
187.84258.34
Bid/Ask
190.20 / 210.00
Prev. Close
194
Open
194
Day's Range
194-194
52 wk Range
187.84-258.34
Volume
1
Average Vol. (3m)
165
1-Year Change
-6.53%
Fair Value
Unlock
Fair Value Upside
Unlock
B1MR34 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
14 analysts have revised their earnings downwards for the upcoming period
Show more

Biomarin Pharmaceutical Inc Company Profile

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Employees
3401
Market
Brazil

Compare B1MR34 to Peers and Sector

Metrics to compare
B1MR34
Peers
Sector
Relationship
P/E Ratio
39.1x−3.3x−0.6x
PEG Ratio
0.330.010.00
Price / Book
2.3x3.0x2.6x
Price / LTM Sales
4.6x3.8x3.3x
Upside (Analyst Target)
-39.6%45.3%
Fair Value Upside
Unlock20.2%6.1%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.7
Dividend Yield
-
Annualized Payout
-
5-Years Growth
-
Growth Streak

FAQ

What Is the Biomarin (B1MR34) Stock Price Today?

The Biomarin stock price today is 194.00

What Stock Exchange Does Biomarin Trade On?

Biomarin is listed and trades on the B3 stock exchange.

What Is the Stock Symbol for Biomarin?

The stock symbol for Biomarin is "B1MR34."

What Is the Biomarin Market Cap?

As of today, Biomarin market cap is 72.62B.

What is Biomarin Earnings Per Share?

The Biomarin EPS is 1.70.

From a Technical Analysis Perspective, Is B1MR34 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.